Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Barun

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Multiple Sclerosis and Related Disorders|March 16, 2024
Characteristics and predictors of sexual dysfunction in men with multiple sclerosisIvan Adamec, Tomislav Sambolić, Mihovil Santini, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 4, 2021
Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational studyGregor Brecl Jakob, Barbara Barun, Sarah Gomezelj, et al.
Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society|September 14, 2018
Autonomic symptom burden is an independent contributor to multiple sclerosis related fatigueMagdalena Krbot Skorić, Luka Crnošija, Ivan Adamec, et al.
Multiple Sclerosis and Related Disorders|September 21, 2025
The impact of national policies on reimbursement of disease-modifying therapies for multiple sclerosis on disease outcomes: Slovenia versus CroatiaGregor Brecl Jakob, Magdalena Krbot Skorić, Ivan Adamec, et al.
Multiple Sclerosis and Related Disorders|November 23, 2019
Intravenous immunoglobulins for the prevention of postpartum relapses in multiple sclerosisAlenka Horvat Ledinek, Gregor Brecl Jakob, Jana Jerše, et al.
Multiple Sclerosis and Related Disorders|March 26, 2026
Long-term outcomes of cladribine tablets in multiple sclerosis: Treatment completion, persistence, and subsequent therapy transitions in Southeast EuropeMagdalena Krbot Skorić, Gregor Brecl Jakob, Cecilia Rajda, et al.
Multiple Sclerosis and Related Disorders|July 24, 2024
Ocrelizumab in people with primary progressive multiple sclerosis: A real-world multicentric studyMagdalena Krbot Skorić, Vanja Bašić Kes, Nevena Grbić, et al.
Journal of Neuroimmunology|August 21, 2021
Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control studyMario Habek, Gregor Jakob Brecl, Vanja Bašić Kes, et al.
Journal of Neuroimmunology|August 3, 2023
Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centersIvan Adamec, Gregor Brecl Jakob, Cecilia Rajda, et al.
European Journal of Neurology|May 22, 2022
Sudomotor dysfunction in people with neuromyelitis optica spectrum disordersMario Habek, Marko Andabaka, Alessandra Fanciulli, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Multiple Sclerosis and Related Disorders|March 16, 2024
Characteristics and predictors of sexual dysfunction in men with multiple sclerosisIvan Adamec, Tomislav Sambolić, Mihovil Santini, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|March 4, 2021
Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational studyGregor Brecl Jakob, Barbara Barun, Sarah Gomezelj, et al.
Clinical Autonomic Research : Official Journal of the Clinical Autonomic Research Society|September 14, 2018
Autonomic symptom burden is an independent contributor to multiple sclerosis related fatigueMagdalena Krbot Skorić, Luka Crnošija, Ivan Adamec, et al.
Multiple Sclerosis and Related Disorders|September 21, 2025
The impact of national policies on reimbursement of disease-modifying therapies for multiple sclerosis on disease outcomes: Slovenia versus CroatiaGregor Brecl Jakob, Magdalena Krbot Skorić, Ivan Adamec, et al.
Multiple Sclerosis and Related Disorders|November 23, 2019
Intravenous immunoglobulins for the prevention of postpartum relapses in multiple sclerosisAlenka Horvat Ledinek, Gregor Brecl Jakob, Jana Jerše, et al.
Multiple Sclerosis and Related Disorders|March 26, 2026
Long-term outcomes of cladribine tablets in multiple sclerosis: Treatment completion, persistence, and subsequent therapy transitions in Southeast EuropeMagdalena Krbot Skorić, Gregor Brecl Jakob, Cecilia Rajda, et al.
Multiple Sclerosis and Related Disorders|July 24, 2024
Ocrelizumab in people with primary progressive multiple sclerosis: A real-world multicentric studyMagdalena Krbot Skorić, Vanja Bašić Kes, Nevena Grbić, et al.
Journal of Neuroimmunology|August 21, 2021
Humoral immune response in convalescent COVID-19 people with multiple sclerosis treated with high-efficacy disease-modifying therapies: A multicenter, case-control studyMario Habek, Gregor Jakob Brecl, Vanja Bašić Kes, et al.
Journal of Neuroimmunology|August 3, 2023
Cladribine tablets in people with relapsing multiple sclerosis: A real-world multicentric study from southeast European MS centersIvan Adamec, Gregor Brecl Jakob, Cecilia Rajda, et al.
European Journal of Neurology|May 22, 2022
Sudomotor dysfunction in people with neuromyelitis optica spectrum disordersMario Habek, Marko Andabaka, Alessandra Fanciulli, et al.
Pageof 6